Effect of Plasmacytoid Dendritic Cell Dose in Grafts on CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation / 中国实验血液学杂志

OBJECTIVE@#To investigate the correlation between plasmacytoid dendritic cell (pDC) dose in grafts and the occurrence of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).@*METHODS@#The clinical data of 80 children who received allo-HSCT in Children's Hospital of Soochow University from August 20, 2020 to June 11, 2021 were retrospectively analyzed. Proportions of DC subsets and T-cell subsets in grafts were detected by flow cytometry in order to calculate infused cell dose of each cell. Weekly monitoring of CMV-DNA copies in peripheral blood for each child were performed after transplantation. The last follow-up date was December 31, 2021.@*RESULTS@#All the children gained hematopoietic reconstitution. CMV infection was observed in 51 children (63.8%±5.4%) within the first 100 days after transplantation, including 2 cases developing CMV disease. Univariate analysis indicated that infused doses of DC and pDC were significantly associated with CMV infection within 100 days after allo-HSCT (P <0.05). Multivariate analysis indicated that a high dose infusion of pDC was an independent protective factor for CMV infection within 100 days after allo-HSCT (P <0.05). By the end of follow-up, 7 children died of transplantation-related complications, including 2 deaths from CMV disease, 2 deaths from extensive chronic graft-versus-host disease, and 3 deaths from capillary leak syndrome. The overall survival rate was 91.2%.@*CONCLUSION@#The pDC in grafts may be associated with early infection of CMV after allo-HSCT, while a high infused pDC dose may serve as a protective factor for CMV infection after transplantation.

Sperm concentration on the intrauterine artificial insemination in swine / Concentrações espermáticas na inseminação artificial intra-uterina suína

The aim of this work was to evaluate the efficiency of the intrauterine insemination (IUI) in swine, considering the conception rate, farrowing rate, litter size (alive born pigs). For the IUI, the females had been insemination at 24 and 48 hours after the estrus detection, and the inseminating doses of 500 million, 1 billion, 1.5 billion and 2 billion spermatozoa in 20 mL extender had been used. The procedure of catheter insertion through the cervical canal was successfully performed in 97.9 percent of the females. The conception rate was 6.3 percent in the IUI. The farrowing rate in IUI was 87.2 percent but the farrowing rate was 100 percent for the sperm concentration of 500 million. Regarding the number of born pigs and alive born pigs observed in females inseminated with IUI, no significant difference was observed (p > 0.05). The concentration of 500 x 10(6) spermatozoa in 20 mL extender in the intrauterine insemination resulted in an optimal reproductive performance.

Conduziu-se este estudo, com o objetivo de avaliar a eficiência da inseminação intra-uterina (IIU) em suínos, considerando as taxas de retorno ao estro, aborto, parto, além do tamanho da leitegada (número de leitões nascidos e nascidos vivos). Na IIU, as fêmeas foram inseminadas nos tempos de 24 e 48 horas após a detecção do estro, utilizando-se as concentrações de 500 milhões, 1 bilhão, 1,5 bilhão e 2 bilhões de espermatozóides, em 20mL de diluente. A passagem do cateter de IIU através da cérvix foi possível em 97,9 por cento das fêmeas. Foi realizado diagnóstico de retorno ao estro a partir do 18º dia e diagnóstico de gestação por ultrassonografia transcutânea entre o 28º e 30º dias após a inseminação. A taxa de retorno ao estro foi de 6,3 por cento na IIU. A taxa de parto na IIU foi de 87,2 por cento, sendo a taxa de parto para a concentração de 500 milhões de 100 por cento. Com relação ao número de leitões nascidos totais e nascidos vivos, não houve diferenças, entre as diferentes concentrações espermáticas (P>0,05). A utilização da concentração de 500 x 10(6) espermatozóides em 20mL de diluente, com inseminação intra-uterina, obteve-se um bom desempenho reprodutivo.

Hematologic Recovery and Clinical Outcomes according to Cell Dose after HLA-matched Sibling Allogeneic Bone Marrow Transplantation

BACKGROUND: There has been changed in estimation of the stem cell content of the graft for several decades. However, there is not always correlating the transplanted cell dose with hematologic recovery, and there are few reports in human leukocyte antigen (HLA)-matched sibling allogeneic bone marrow transplantation (AlloBMT) in Korea. The purpose of this study is to report the influence of number of transplanted cell dose on hematologic recovery and the clinical outcomes in HLA-matched sibling AlloBMT. METHODS: Between June 1999 and March 2004, 31 AlloBMT from HLA-matched sibling donor was done in patients with hematologic malignancy. All patients were conditioned with busulfan and cyclophosphamide. Short course methotrexate and cyclosporine regimen was used for prophylaxis of graft-versus-host disease. We analyzed hematologic recovery time and clinical outcomes according to transplanted cell dose. RESULTS: There were 16 male and 15 female patients, with a median age of 34 years (range, 16~48). Underlying diseases were 17 acute myeloid leukemia, 4 acute lymphoblastic leukemia, 3 myelodysplastic syndrome (high-risk), and 7 chronic myelogenous leukemia. The median number of total nucleated cell (TNC), mononuclear cell (MNC) and CD34+ cell infused was 3.95x10(8)/kg (range, 1.67~7.30x10(8)/kg), 0.65x10(8)/kg (range, 0.11~2.50x10(8)/kg), and 2.32x106/kg (range, 0.35~7.45x106/kg), respectively. The median days of neutrophil and platelet engraftment (ANC>500/microliter and platelet > 20,000/L without transfusion) were 15 (range, 10~19), 16 (range, 7~37), respectively. Relationship between the rate of neutrophil engraftment and the number of infused TNC was only statistically significant (P=0.038, R2=0.328). This study showed survival benefit with the increment of CD34+ cell dose without significance statistically (P=0.082). CONCLUSION: Although the dose of the number of transplanted MNC and CD34+ cells had no influence on granulocyte or platelet recovery, the number of TNC had only a beneficial effect on neutrophil recovery. The transplanted dose of CD34+ cells, rather than those of TNC and MNC may be related with better survival.

Clinical Outcomes according to Transplanted CD34+ Cell Dose in Allogeneic Peripheral Blood Stem Cell Transplantation / 대한혈액학회지

BACKGROUND: Recently, allogeneic peripheral blood stem cell transplantation (Allo-PBSCT) instead of bone marrow transplantation (BMT) has been widely used with the benefits of an earlier recovery of blood cells and a lower incidence of graft failure because of higher CD34+ cell dose. However, recent studies suggested that the higher dose of CD34+ cells might be related to the lower survival and the higher morbidity due to chronic graft versus host disease (cGVHD). We have analyzed the impact of transplanted CD34+ cell dose on clinical outcomes in unmanipulated allo-PBSCT from HLA identical siblings. METHODS: Thirty-one consecutive adult patients with hematological diseases, who survived until at least day 90 after allo-PBSCT and were evaluable for cGVHD, were included. Peripheral blood stem cells were collected from HLA-matched sibling donors mobilized with G-CSF and/or GM-CSF. The patients were classified into a "low" or "high" CD34+ cell dose group based on whether they received less or more than a median CD34+ cell dose of 11.17X10(6)/kg, respectively. RESULTS: The median CD34+ cell dose was 11.17X10(6)/kg (range, 4.12-58.80X10(6)/kg). Acute GVHD (grade II-IV) appeared in 24 patients (77.4%) and extensive cGVHD in 14 patients (45.2%). During the follow-up (median: 340 days, range: 111-1263 days), relapses were observed in 12 patients (38.7%) and 19 patients are still alive. There was a significant difference in the incidence of extensive cGVHD (20.0% vs 68.8%, P=0.011) and relapse (60.0% vs 18.8%, P=0.029) between low and high CD34+ cell dose groups, but no difference of the incidence of acute GVHD or the days of engraftments between the two groups. The estimated survival rate was significantly different between the two groups (3 year survival rate, 31.5% vs 79.8%, P=0.022) and the patients with extensive cGVHD showed a higher survival rate than those without extensive cGVHD (55.6% vs 12.5%, P=0.013). CONCLUSION: Better survival rate was observed in high CD34+ cell dose group for alloPBSCT, while a higher incidence of extensive cGVHD was noted. The optimal dose of CD34+ cells need to be determined to minimize the morbidity related to cGVHD and to improve survival.